Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.8K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Vascular Spasm01:16

Vascular Spasm

3.4K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.

Blood·2026
Same author

Red Blood Cell Transfusion Characteristics and Morbidity or Mortality in Very-Low-Birth-Weight Infants.

JAMA network open·2026
Same author

Association between vaccine-induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?

British journal of haematology·2026
Same author

A three-dimensional shear dependent continuum model of platelet aggregation under flow.

PLoS computational biology·2026
Same author

Proteomic profiling identifies systemic drivers of blood-brain barrier injury in sickle cell disease.

Blood·2026
Same author

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

Biophysical journal·2026
Same journal

Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study.

Blood vessels, thrombosis & hemostasis·2026
Same journal

NETs contribute to acute episodes but not ADAMTS13 relapses in immune-mediated thrombotic thrombocytopenic purpura.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Immune-mediated acute thrombocytopenia within 30 minutes of first obinutuzumab infusion.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Successful eltrombopag discontinuation in paraneoplastic immune thrombocytopenia: a case report.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Impact of ABO blood groups on residual pulmonary vascular obstruction in patients with unprovoked pulmonary embolism.

Blood vessels, thrombosis & hemostasis·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages
06:47

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages

Published on: May 24, 2019

7.7K

iMer, a naturally occurring MERTK splice variant, binds to GAS6 to decrease platelet activation and thrombus

Stephanie Springborn1, Samantha Judd1, Patricia Morateck1

  • 1Hematology, Thrombosis and Hemostasis Research Program, Versiti Blood Research Institute, Wauwatosa, WI.

Blood Vessels, Thrombosis & Hemostasis
|September 8, 2025
PubMed
Summary
This summary is machine-generated.

A novel MERTK variant, iMer, inhibits platelet activation and thrombus formation by acting as a GAS6 decoy. This finding suggests targeting the GAS6/MERTK pathway may offer new treatments for thrombosis.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.0K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages
06:47

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages

Published on: May 24, 2019

7.7K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.0K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.6K

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Platelet activation is crucial for hemostasis but can lead to pathological thrombosis when unopposed.
  • The Growth Arrest-Specific Gene 6 (GAS6)/Mer receptor tyrosine kinase (MERTK) pathway plays a significant role in platelet activation and thrombus stabilization.

Purpose of the Study:

  • To investigate the role of a naturally occurring MERTK splice variant, iMer, in regulating platelet function and thrombus formation.
  • To explore the therapeutic potential of iMer in preventing thrombosis.

Main Methods:

  • Incubation of human and murine platelets with iMer, a truncated GAS6 decoy receptor.
  • Ex vivo platelet function assays including aggregometry, P-selectin expression, and collagen-induced spreading.
  • In vivo studies using a collagen/epinephrine-induced pulmonary embolism mouse model to assess survival and bleeding times.

Main Results:

  • iMer significantly reduced platelet activation in ex vivo assays, comparable to anti-GAS6 antibody treatment.
  • iMer treatment improved survival in a mouse model of pulmonary embolism without increasing bleeding time.
  • iMer acts by decreasing MERTK phosphorylation, thereby inhibiting platelet activation.

Conclusions:

  • The GAS6/MERTK signaling pathway is critical for platelet activation and thrombus formation.
  • iMer, by acting as a GAS6 decoy, effectively inhibits platelet function and thrombus stabilization.
  • Targeting the GAS6/MERTK pathway with agents like iMer holds therapeutic promise for treating and preventing thrombosis.